PMC:7253482 / 1814-2197
Annnotations
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"67","span":{"begin":367,"end":372},"obj":"Gene"},{"id":"76","span":{"begin":54,"end":64},"obj":"Species"},{"id":"77","span":{"begin":198,"end":204},"obj":"Species"},{"id":"79","span":{"begin":79,"end":88},"obj":"Disease"}],"attributes":[{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"Gene:43740568"},{"id":"A76","pred":"tao:has_database_id","subj":"76","obj":"Tax:2697049"},{"id":"A77","pred":"tao:has_database_id","subj":"77","obj":"Tax:9606"},{"id":"A79","pred":"tao:has_database_id","subj":"79","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"coronavirus (MERS-CoV) in 20123, and most recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) protei"}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T10","span":{"begin":54,"end":62},"obj":"Disease"},{"id":"T11","span":{"begin":54,"end":58},"obj":"Disease"}],"attributes":[{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"coronavirus (MERS-CoV) in 20123, and most recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) protei"}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T10","span":{"begin":198,"end":204},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T11","span":{"begin":354,"end":359},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"}],"text":"coronavirus (MERS-CoV) in 20123, and most recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) protei"}
LitCovid-sample-PD-IDO
{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T8","span":{"begin":307,"end":316},"obj":"http://purl.obolibrary.org/obo/IDO_0000528"}],"text":"coronavirus (MERS-CoV) in 20123, and most recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) protei"}
LitCovid-sample-Enju
{"project":"LitCovid-sample-Enju","denotations":[{"id":"T273","span":{"begin":0,"end":11},"obj":"NN"},{"id":"T274","span":{"begin":12,"end":13},"obj":"-LRB-"},{"id":"T275","span":{"begin":13,"end":21},"obj":"NN"},{"id":"T276","span":{"begin":21,"end":22},"obj":"-RRB-"},{"id":"T277","span":{"begin":23,"end":25},"obj":"IN"},{"id":"T278","span":{"begin":26,"end":31},"obj":"CD"},{"id":"T279","span":{"begin":31,"end":32},"obj":"-COMMA-"},{"id":"T280","span":{"begin":33,"end":36},"obj":"CC"},{"id":"T281","span":{"begin":37,"end":41},"obj":"RBS"},{"id":"T282","span":{"begin":42,"end":50},"obj":"RB"},{"id":"T283","span":{"begin":51,"end":53},"obj":"IN"},{"id":"T284","span":{"begin":54,"end":65},"obj":"NN"},{"id":"T285","span":{"begin":67,"end":72},"obj":"VBN"},{"id":"T286","span":{"begin":73,"end":78},"obj":"PRP-DOLLAR-"},{"id":"T287","span":{"begin":79,"end":88},"obj":"NN"},{"id":"T288","span":{"begin":89,"end":94},"obj":"NNS"},{"id":"T289","span":{"begin":94,"end":95},"obj":"-COMMA-"},{"id":"T290","span":{"begin":96,"end":99},"obj":"DT"},{"id":"T291","span":{"begin":100,"end":107},"obj":"JJ"},{"id":"T292","span":{"begin":108,"end":112},"obj":"NN"},{"id":"T293","span":{"begin":113,"end":115},"obj":"IN"},{"id":"T294","span":{"begin":116,"end":124},"obj":"VBN"},{"id":"T295","span":{"begin":125,"end":135},"obj":"NNS"},{"id":"T296","span":{"begin":136,"end":139},"obj":"CC"},{"id":"T297","span":{"begin":140,"end":148},"obj":"JJ"},{"id":"T298","span":{"begin":149,"end":157},"obj":"NNS"},{"id":"T299","span":{"begin":157,"end":158},"obj":"-COMMA-"},{"id":"T300","span":{"begin":159,"end":162},"obj":"CC"},{"id":"T301","span":{"begin":163,"end":168},"obj":"PRP-DOLLAR-"},{"id":"T302","span":{"begin":169,"end":177},"obj":"NN"},{"id":"T303","span":{"begin":178,"end":180},"obj":"TO"},{"id":"T304","span":{"begin":181,"end":189},"obj":"VB"},{"id":"T305","span":{"begin":190,"end":197},"obj":"IN"},{"id":"T306","span":{"begin":198,"end":204},"obj":"NNS"},{"id":"T307","span":{"begin":205,"end":208},"obj":"CC"},{"id":"T308","span":{"begin":209,"end":215},"obj":"IN"},{"id":"T309","span":{"begin":216,"end":223},"obj":"NNS"},{"id":"T310","span":{"begin":224,"end":235},"obj":"NN"},{"id":"T311","span":{"begin":235,"end":236},"obj":"-COMMA-"},{"id":"T312","span":{"begin":237,"end":242},"obj":"EX"},{"id":"T313","span":{"begin":243,"end":245},"obj":"VBZ"},{"id":"T314","span":{"begin":246,"end":248},"obj":"DT"},{"id":"T315","span":{"begin":249,"end":255},"obj":"JJ"},{"id":"T316","span":{"begin":256,"end":260},"obj":"NN"},{"id":"T317","span":{"begin":261,"end":264},"obj":"IN"},{"id":"T318","span":{"begin":265,"end":274},"obj":"JJ"},{"id":"T319","span":{"begin":275,"end":290},"obj":"NNS"},{"id":"T320","span":{"begin":291,"end":293},"obj":"TO"},{"id":"T321","span":{"begin":294,"end":300},"obj":"VB"},{"id":"T322","span":{"begin":301,"end":306},"obj":"DT"},{"id":"T323","span":{"begin":307,"end":316},"obj":"NNS"},{"id":"T324","span":{"begin":318,"end":325},"obj":"VBG"},{"id":"T325","span":{"begin":326,"end":333},"obj":"NN"},{"id":"T326","span":{"begin":334,"end":345},"obj":"NN"},{"id":"T327","span":{"begin":346,"end":353},"obj":"NNS"},{"id":"T328","span":{"begin":354,"end":359},"obj":"NN"},{"id":"T329","span":{"begin":360,"end":362},"obj":"IN"},{"id":"T330","span":{"begin":363,"end":366},"obj":"DT"},{"id":"T331","span":{"begin":367,"end":372},"obj":"NN"},{"id":"T332","span":{"begin":373,"end":374},"obj":"-LRB-"},{"id":"T333","span":{"begin":374,"end":375},"obj":"NN"},{"id":"T334","span":{"begin":375,"end":376},"obj":"-RRB-"}],"relations":[{"id":"R268","pred":"arg1Of","subj":"T273","obj":"T274"},{"id":"R269","pred":"arg2Of","subj":"T275","obj":"T274"},{"id":"R270","pred":"arg3Of","subj":"T276","obj":"T274"},{"id":"R271","pred":"arg1Of","subj":"T273","obj":"T277"},{"id":"R272","pred":"arg2Of","subj":"T278","obj":"T277"},{"id":"R273","pred":"arg1Of","subj":"T280","obj":"T279"},{"id":"R274","pred":"arg1Of","subj":"T277","obj":"T280"},{"id":"R275","pred":"arg2Of","subj":"T283","obj":"T280"},{"id":"R276","pred":"arg1Of","subj":"T282","obj":"T281"},{"id":"R277","pred":"arg1Of","subj":"T283","obj":"T282"},{"id":"R278","pred":"arg1Of","subj":"T273","obj":"T283"},{"id":"R279","pred":"arg2Of","subj":"T284","obj":"T283"},{"id":"R280","pred":"arg1Of","subj":"T313","obj":"T285"},{"id":"R281","pred":"arg2Of","subj":"T300","obj":"T285"},{"id":"R282","pred":"arg1Of","subj":"T288","obj":"T286"},{"id":"R283","pred":"arg1Of","subj":"T288","obj":"T287"},{"id":"R284","pred":"arg1Of","subj":"T288","obj":"T289"},{"id":"R285","pred":"arg2Of","subj":"T292","obj":"T289"},{"id":"R286","pred":"arg1Of","subj":"T292","obj":"T290"},{"id":"R287","pred":"arg1Of","subj":"T292","obj":"T291"},{"id":"R288","pred":"arg1Of","subj":"T292","obj":"T293"},{"id":"R289","pred":"arg2Of","subj":"T296","obj":"T293"},{"id":"R290","pred":"arg2Of","subj":"T295","obj":"T294"},{"id":"R291","pred":"arg1Of","subj":"T295","obj":"T296"},{"id":"R292","pred":"arg2Of","subj":"T298","obj":"T296"},{"id":"R293","pred":"arg1Of","subj":"T298","obj":"T297"},{"id":"R294","pred":"arg1Of","subj":"T300","obj":"T299"},{"id":"R295","pred":"arg1Of","subj":"T289","obj":"T300"},{"id":"R296","pred":"arg2Of","subj":"T302","obj":"T300"},{"id":"R297","pred":"arg1Of","subj":"T302","obj":"T301"},{"id":"R298","pred":"arg1Of","subj":"T304","obj":"T303"},{"id":"R299","pred":"modOf","subj":"T302","obj":"T303"},{"id":"R300","pred":"arg1Of","subj":"T304","obj":"T305"},{"id":"R301","pred":"arg2Of","subj":"T306","obj":"T305"},{"id":"R302","pred":"arg1Of","subj":"T285","obj":"T307"},{"id":"R303","pred":"arg2Of","subj":"T308","obj":"T307"},{"id":"R304","pred":"arg1Of","subj":"T313","obj":"T308"},{"id":"R305","pred":"arg2Of","subj":"T310","obj":"T308"},{"id":"R306","pred":"arg1Of","subj":"T310","obj":"T309"},{"id":"R307","pred":"arg1Of","subj":"T313","obj":"T311"},{"id":"R308","pred":"arg1Of","subj":"T312","obj":"T313"},{"id":"R309","pred":"arg2Of","subj":"T316","obj":"T313"},{"id":"R310","pred":"arg1Of","subj":"T316","obj":"T314"},{"id":"R311","pred":"arg1Of","subj":"T316","obj":"T315"},{"id":"R312","pred":"arg1Of","subj":"T316","obj":"T317"},{"id":"R313","pred":"arg2Of","subj":"T319","obj":"T317"},{"id":"R314","pred":"arg3Of","subj":"T321","obj":"T317"},{"id":"R315","pred":"arg1Of","subj":"T319","obj":"T318"},{"id":"R316","pred":"arg1Of","subj":"T321","obj":"T320"},{"id":"R317","pred":"arg1Of","subj":"T319","obj":"T321"},{"id":"R318","pred":"arg2Of","subj":"T323","obj":"T321"},{"id":"R319","pred":"arg1Of","subj":"T323","obj":"T322"},{"id":"R320","pred":"arg1Of","subj":"T328","obj":"T324"},{"id":"R321","pred":"arg1Of","subj":"T328","obj":"T325"},{"id":"R322","pred":"arg1Of","subj":"T328","obj":"T326"},{"id":"R323","pred":"arg1Of","subj":"T328","obj":"T327"},{"id":"R324","pred":"arg1Of","subj":"T328","obj":"T329"},{"id":"R329","pred":"arg2Of","subj":"T333","obj":"T332"},{"id":"R330","pred":"arg3Of","subj":"T334","obj":"T332"}],"text":"coronavirus (MERS-CoV) in 20123, and most recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) protei"}
LitCovid-sample-PD-NCBITaxon
{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T16","span":{"begin":13,"end":21},"obj":"Species"},{"id":"T17","span":{"begin":54,"end":62},"obj":"Species"},{"id":"T18","span":{"begin":54,"end":58},"obj":"Species"},{"id":"T19","span":{"begin":198,"end":204},"obj":"Species"}],"attributes":[{"id":"A16","pred":"ncbi_taxonomy_id","subj":"T16","obj":"NCBItxid:1335626"},{"id":"A17","pred":"ncbi_taxonomy_id","subj":"T17","obj":"NCBItxid:694009"},{"id":"A18","pred":"ncbi_taxonomy_id","subj":"T18","obj":"NCBItxid:694009"},{"id":"A19","pred":"ncbi_taxonomy_id","subj":"T19","obj":"NCBItxid:9605"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"coronavirus (MERS-CoV) in 20123, and most recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) protei"}
LitCovid-sample-sentences
{"project":"LitCovid-sample-sentences","denotations":[{"id":"T14","span":{"begin":67,"end":317},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"coronavirus (MERS-CoV) in 20123, and most recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) protei"}
LitCovid-sample-PD-MONDO
{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T10","span":{"begin":54,"end":62},"obj":"Disease"},{"id":"T11","span":{"begin":54,"end":58},"obj":"Disease"}],"attributes":[{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"coronavirus (MERS-CoV) in 20123, and most recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) protei"}
LitCovid-sample-Pubtator
{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"76","span":{"begin":54,"end":64},"obj":"Species"},{"id":"79","span":{"begin":79,"end":88},"obj":"Disease"},{"id":"77","span":{"begin":198,"end":204},"obj":"Species"},{"id":"67","span":{"begin":367,"end":372},"obj":"Gene"}],"attributes":[{"id":"A76","pred":"pubann:denotes","subj":"76","obj":"Tax:2697049"},{"id":"A79","pred":"pubann:denotes","subj":"79","obj":"MESH:D003643"},{"id":"A77","pred":"pubann:denotes","subj":"77","obj":"Tax:9606"},{"id":"A67","pred":"pubann:denotes","subj":"67","obj":"Gene:43740568"}],"text":"coronavirus (MERS-CoV) in 20123, and most recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) protei"}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T14","span":{"begin":67,"end":317},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"coronavirus (MERS-CoV) in 20123, and most recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) protei"}